Latest News: Proscia Receives FDA 510(k) Clearance For Concentriq AP-DxREAD THE PRESS RELEASE

Proscia’s Digital Pathology System Obtains CE Mark

By Author Proscia | November 7, 2019

Proscia has received a CE Mark for its Concentriq Dx solution for use in primary diagnosis. The CE Mark indicates that Concentriq Dx complies with the European In Vitro Diagnostic Regulations. Read more here:

Our website uses cookies. By using this site, you agree to its use of cookies.